US Stock MarketDetailed Quotes

GSK GlaxoSmithKline

Watchlist

36.170
-0.380-1.04%

Close Feb 14 16:00 ET

36.210
+0.040+0.11%

Post 20:01 ET

73.82BMarket Cap23.10P/E (TTM)

GlaxoSmithKline Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

GlaxoSmithKline Q4 2024 Earnings Date

Currency：USDFeb 5, 2025

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	9.73B	10.19B	+459.67M
Beat Est.	-5.11%	-0.62%	+4.73%
EPS	0.51	0.25	-0.25
Miss Est.	+131.90%	+15.98%	-50.33%

Analyst Rating

Hold

Feb 17, 2025

GlaxoSmithKline Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: GBP

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q2	-- / 7.993B	--
--	2025/Q1	-- / 7.575B	--
Feb 5, 2025	2024/Q4	8.117B / 7.751B	--
Oct 30, 2024	2024/Q3	8.012B / 8.007B	--
Jul 31, 2024	2024/Q2	7.884B / 7.493B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q2-- / 7.993B--

--2025/Q1-- / 7.575B--

Feb 5, 20252024/Q48.117B / 7.751B--

Oct 30, 20242024/Q38.012B / 8.007B--

Jul 31, 20242024/Q27.884B / 7.493B--

Unlock Free Earnings Estimates

Open Account

GlaxoSmithKline Earnings Reports

6-K: Gsk Delivers Strong 2024 Performance with Further Improvement to Long-Term Growth Outlook

Feb 5 12:00 ET

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

Oct 30, 2024 11:27 ET

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

Jul 31, 2024 12:31 ET

6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year

May 1, 2024 12:34 ET

Trending Stocks

Symbol Mini Chart % Chg

DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS

Unlock the Full List

Analysis

Analyst Rating

Updated: Feb 17, 2025

Hold

Buy
25.00%
Hold
50.00%
Sell
25.00%

Price Target

No Data